Glycemic control and use of glucose-lowering medications in hospital-admitted type 2 diabetes patients over 80 years

被引:5
|
作者
Gotfredsen, Ditte Resendal [1 ]
Vinther, Siri [1 ]
Petersen, Tonny Studsgaard [1 ,2 ]
Cortes, Rikke [1 ]
Jensen, Thomas Bo [1 ,2 ]
Jimenez-Solem, Espen [1 ,2 ]
Christensen, Mikkel Bring [1 ,2 ,3 ]
机构
[1] Bispebjerg & Frederiksberg Hosp, Dept Clin Pharmacol, Copenhagen, Denmark
[2] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark
[3] Univ Copenhagen, Gentofte Hosp, Ctr Clin Metab Res, Hellerup, Denmark
关键词
OLDER-ADULTS; SEVERE HYPOGLYCEMIA; POTENTIAL OVERTREATMENT; MELLITUS; TRENDS; PEOPLE; ASSOCIATION; PREVALENCE; GUIDELINES; EVENTS;
D O I
10.1038/s41598-020-60818-5
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Treatment guidelines for type 2 diabetes (T2D) recommend avoidance of hypoglycemia and less stringent glycemic control in older patients. We examined the relation of glycemic control to glucose-lowering medications use in a cohort of patients aged>80 years with a diagnosis of T2D and a hospital admission in the Capital Region of Denmark in 2012-2016. We extracted data on medication use, diagnoses, and biochemistry from the hospitals' records. We identified 5,172 T2D patients with high degree of co-morbidity and where 17% had an HbA(1c) in the range recommended for frail, comorbid, older patients with type 2 diabetes (58-75 mmol/mol (7.5-9%)). Half of the patients (n = 2,575) had an HbA1c <48 mmol/mol (<6.5%), and a majority of these (36% of all patients) did not meet the diagnostic criteria for T2D. Of patients treated with one or more glucose-lowering medications (n = 1,758), 20% had HbA(1c)-values <42 mmol/mol (<6%), and 1% had critically low Hba(1c) values <30 mmol/mol (<4.9%), In conclusion, among these hospitalized T2D patients, few had an HbA(1c) within the generally recommended glycemic targets. One third of patients did not meet the diagnostic criteria for T2D, and of the patients who were treated with glucose-lowering medications, one-fifth had HbA(1c)-values suggesting overtreatment.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals
    Meloni, Alison R.
    DeYoung, Mary Beth
    Han, Jenny
    Best, Jennie H.
    Grimm, Michael
    CARDIOVASCULAR DIABETOLOGY, 2013, 12
  • [22] Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals
    Alison R Meloni
    Mary Beth DeYoung
    Jenny Han
    Jennie H Best
    Michael Grimm
    Cardiovascular Diabetology, 12
  • [23] Concomitant use of benzodiazepines and oral glucose-lowering drugs in patients with type-2 diabetes
    Fornero, Agostina
    Bertoldo, Pamela
    Dumont, Nilda
    FARMACEUTICOS COMUNITARIOS, 2018, 10 (01): : 41 - 46
  • [24] Glucose-lowering effects of sulfasalazine in type 2 diabetes
    Haas, RM
    Li, P
    Chu, JW
    DIABETES CARE, 2005, 28 (09) : 2238 - 2239
  • [25] Future glucose-lowering drugs for type 2 diabetes
    Bailey, Clifford J.
    Tahrani, Abd A.
    Barnett, Anthony H.
    LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (04): : 350 - 359
  • [26] Factors Influencing the Selection of Glucose-Lowering Medications among Physicians Treating Patients with Type 2 Diabetes in Real World
    Abudahesh, Joud A.
    Aijebreen, Joud A.
    Alhalees, Danah Z.
    Albraithen, Ghaida
    Bamogaddam, Ghada S.
    Al-Sofiani, Mohammed
    DIABETES, 2022, 71
  • [27] Glucose-Lowering Medications and Post-Dementia Survival in Patients with Diabetes and Dementia
    Secnik, Juraj
    Xu, Hong
    Schwertner, Emilia
    Hammar, Niklas
    Alvarsson, Michael
    Winblad, Bengt
    Eriksdotter, Maria
    Garcia-Ptacek, Sara
    Religa, Dorota
    JOURNAL OF ALZHEIMERS DISEASE, 2022, 86 (01) : 245 - 257
  • [28] Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes
    Tomlinson, Brian
    Hu, Miao
    Zhang, Yuzhen
    Chan, Paul
    Liu, Zhong-Min
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (11) : 1267 - 1271
  • [29] Personalizing Glucose-Lowering Therapy in Patients with Type 2 Diabetes and Cardiovascular Disease
    Inzucchi, Silvio E.
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2018, 47 (01) : 137 - +
  • [30] The Glucose-lowering Efficacy of Sitagliptin in Obese Japanese Patients with Type 2 Diabetes
    Kodera, Ryo
    Shikata, Kenichi
    Nakamura, Akihiko
    Okazaki, Satoru
    Nagase, Ryo
    Nakatou, Tatsuaki
    Haisa, Shigeru
    Hida, Kazuyuki
    Miyashita, Katsuhiro
    Makino, Hirofumi
    INTERNAL MEDICINE, 2017, 56 (06) : 605 - 613